Tuesday, November 17, 2026

Geneoscopy, Exact Sciences: All Patent Claims Settled ("Obviousness")

On November 17, 2026, a press release from Geneoscopy announces the settlement of claims and counterclaims between the two companies.

Pivotal steps along the legal pathway were PTO rulings that two major Exact patents, '746 and '781, failed a judicial review for "obviousness."   Obviously, the same patents had passed their patent reviews.  What changed?  What was most important, when they came to the courtroom for litigation?

We found key court documents and uploaded to Chat GPT 6 for discussion.

The patents remind us that, just the basic business of preserving nucleic acids during shipping, in the stool biospecimen, is a big hurdle and not to be taken lightly.   

###

I am not an attorney, nor is Chat GPT.  For the chance to read an AI report on this topic, Chat GPT writes...

###

Geneoscopy and Exact Sciences Settle:
A Closer Look at Patent “Obviousness”

On November 17, 2026, GenomeWeb reported that Geneoscopy and Exact Sciences had settled all pending litigation between them in federal district court. The dispute involved their competing stool-based colorectal cancer screening products, ColoSense and Cologuard. According to Geneoscopy’s announcement, the settlement includes no admission of liability or wrongdoing, and its other terms remain confidential.

Two earlier patent decisions formed an important backdrop. In July 2025 and February 2026, the Patent Trial and Appeal Board found the challenged claims of two Exact Sciences patents unpatentable as obvious. Those rulings eliminated the patent claims Exact had asserted against Geneoscopy, although other aspects of the litigation continued until the settlement. The confidential terms do not establish precisely how much weight each issue carried in the parties’ negotiations. www.prnewswire.com

The original judgments offer an instructive look at a question extending well beyond these companies: How can an invention pass examination at the Patent Office, yet later be found obvious by another body within that same office?

PatentOriginal judgmentOutcome
11,634,781, or ’781July 9, 2025; IPR2024-00459All 20 claims found unpatentable
11,970,746, or ’746February 5, 2026; IPR2024-01330All 10 challenged claims found unpatentable

The original USPTO documents are linked here: ’781 final judgment, ’746 final judgment, and the earlier July 2024 decision instituting review of ’781. The discussion below draws directly from these documents.

“Obvious” has a specific legal meaning. It does not necessarily mean that an invention was easy to develop, inexpensive to validate, or unimportant to patients. The question is whether the claimed invention would have been obvious to a hypothetical person of ordinary skill in the field, considering the knowledge available at the relevant historical time.

A combination can be new in the sense that no single earlier publication describes the entire arrangement, yet still be obvious if a skilled person would have had reason to combine earlier teachings and reasonably expect the combination to work. Conversely, merely locating all the ingredients in scattered publications is insufficient: the reasoning connecting them matters. The USPTO’s detailed examination guidance (21pp) requires a reasoned explanation supporting that connection.

The cases concerned methods for collecting, preserving, and processing stool samples for blood-protein and nucleic-acid testing. In simplified terms, the methods involved home collection, separate sample portions, and preservation appropriate to the different analytes. The ’746 claims also addressed subsequent laboratory extraction and testing.

The Framing Matters

That framing matters. The Board was evaluating particular patent claims, rather than deciding whether Cologuard as a complete clinical product was innovative or valuable.

The challenger's case combined several earlier sources. 

  • Lenhard described combining stool DNA methylation analysis with fecal occult blood testing. 
  • Vilkin described immunochemical blood testing, including a collection device and hemoglobin-stabilizing buffer. 
  • Itzkowitz described home stool collection and DNA stabilization that permitted shipment without freezing. Other references supplied additional features for particular claims.

The Board concluded that these teachings provided both the necessary components and reasons to bring them together. Improved blood testing, preservation of DNA, and more convenient collection addressed recognized problems in colorectal cancer screening.

Exact Argued Back...

Exact disputed that reasoning. Its arguments included the complexity of combining tests, uncertainty about performance, additional patient handling of stool, and the possibility that the challenger was reconstructing the invention with hindsight. These are substantive objections: a technically possible combination is not automatically one a skilled person would have pursued.

The Board nevertheless found the record sufficient to support the combinations. Its analysis appears particularly clearly in the ’781 judgment at printed pages 46–55 and the ’746 judgment at pages 51–61.

The ’746 decision contains an especially accessible example: could a better alternative make the claimed approach nonobvious?

Exact argued that a skilled person would have looked toward a single preservative capable of protecting both hemoglobin and nucleic acids, rather than separate portions with respective preservatives. The Board acknowledged that this argument made sense in the abstract and discussed evidence suggesting a single-buffer approach might have been possible.

But the Board rejected the inference that the availability of such an alternative made the two-portion approach nonobvious. An earlier combination need not be the best possible option to qualify as obvious; it can be a suitable option supported by the existing knowledge.

That distinction is useful outside patent law as well. Showing that another design might be preferable does not establish that the chosen design required an inventive step.

Cologuard’s commercial success presented a different question.

Exact offered evidence of commercial success, industry praise, satisfaction of a longstanding need, and alleged copying. Patent law permits such evidence to support nonobviousness. It can help prevent a decision maker from declaring an achievement obvious only after seeing someone successfully accomplish it.

The difficulty was establishing a sufficiently close connection—called a nexus—between that evidence and the particular claimed invention.

The Board recognized that Cologuard used aspects of the claimed methods. In the ’781 decision, it also acknowledged that the collection steps could contribute to ease of use and consumer friendliness. But Cologuard incorporated many additional features and was covered by numerous other patents.

In both judgments, the Board emphasized Exact’s earlier statements attributing important aspects of Cologuard’s success to particular markers, extraction methods, reagents, and algorithm components outside the claims under review. It found that Exact had not adequately established the required connection between the product’s success and these particular claims.

The reasoning was narrower than a conclusion that commercial success was irrelevant. Success could matter, but the evidence had to explain why it supported the nonobviousness of the invention actually claimed. The relevant discussions appear at pages 23–34 of ’781 and 27–40 of ’746.

The examiner had previously reached a favorable result—and not only at original issuance.

The ’781 patent also survived an examiner’s ex parte reexamination in 2023. As summarized in the July 2024 institution decision, the examiner found that the references then presented did not adequately suggest home collection with separate sealed portions, each containing a buffer.

When Geneoscopy subsequently requested inter partes review, Exact argued that the Patent Office had already considered substantially the same material.

The Board examined that objection. It acknowledged that some references had previously been disclosed, but distinguished Vilkin’s express description of a hemoglobin-stabilizing buffer from more generic buffer descriptions in earlier material. It also found differences in the combinations and arguments presented. It therefore allowed the review to proceed.

  • This history illustrates why “the examiner already approved it” does not end the inquiry.
  • The later proceeding can present a different evidentiary record and a more developed adversarial examination of how the references fit together.

The procedural distinction is also important. Inter partes review, meaning review “between the parties,” is an administrative trial before patent judges within the USPTO. It is separate from federal district-court litigation over infringement. IPR is limited to specified "patentability" challenges based on patents and printed publications; it does not award infringement damages.

The burden of proof also differs. In IPR, the challenger must establish unpatentability by a preponderance of the evidence. In district court, patent invalidity generally requires clear and convincing evidence. Thus, the substantive concept of obviousness operates within different procedural settings. www.uspto.gov

Summing it up

The Geneoscopy–Exact Sciences dispute leaves a useful case study for diagnostics readers. Clinical development, regulatory approval, commercial adoption, and patentability each ask different questions. These judgments show how closely an obviousness inquiry can turn on the wording of claims, the details of earlier publications, the reasons for combining known methods, and the connection between a successful product and the particular invention for which exclusivity is sought.

#     #     #     #     #

##

Sidebar 01

Intra partes was created recently?   
Steer some cases away from federal courts?

Yes—modern inter partes review is relatively recent, and providing an alternative to costly federal litigation was an explicit purpose. The term is inter partes (“between the parties”).

Congress created today’s inter partes review, or IPR, in the America Invents Act of 2011, effective September 16, 2012. It replaced an earlier procedure called inter partes reexamination, established in 1999. Administrative reexamination itself dates to legislation enacted in 1980. uspto.gov

Your interpretation captures much of the rationale. Congress wanted a “quick and cost-effective” alternative to litigation, while improving patent quality and giving the Patent Office a practical way to reconsider patents that should not have issued. Relieving litigation costs and burdens was part of that broader purpose. govinfo.gov

Two qualifications matter:

  • IPR did not remove these issues from federal courts. Courts can still decide obviousness and other invalidity defenses. IPR provides an additional administrative route, sometimes pursued alongside a lawsuit.
  • Its scope is deliberately narrow: anticipation or obviousness based on earlier patents and printed publications. 
    • Questions of infringement, damages, and other invalidity grounds fall outside IPR’s scope. AMERICA INVENTS ACT

The Geneoscopy dispute illustrates that division: PTAB considered whether the challenged patent claims should survive, while the Delaware court handled the broader dispute between the companies.

For the blog, this could be expressed as:

The administrative route used in these cases is relatively recent. Congress created modern inter partes review in 2011, effective in 2012, partly to provide a faster, less expensive alternative to federal litigation over patent validity. It allows specialized patent judges within the Patent Office to reconsider issued claims using earlier patents and publications. Federal courts retain authority to decide validity, but IPR provides a focused proceeding in which those technical questions can be resolved separately from infringement, damages, and other commercial disputes.

What if Geneoscopy had "lost" its 781 or 741 case with PTO IPR judge?

 Had Geneoscopy lost a final IPR decision on ’781, the route would have been:

  1. Optional USPTO reconsideration: Request rehearing by the Board or review by the USPTO Director.
  2. Appeal directly to the U.S. Court of Appeals for the Federal Circuit, generally within 63 days. A timely reconsideration request resets the appeal deadline. 
    1. This is appellate review of the PTAB record, rather than a new district-court trial. uscode.house.gov
  3. After an adverse appellate decision: Seek panel rehearing or rehearing by the full Federal Circuit, then potentially petition the U.S. Supreme Court, which can decline review.

Losing the IPR would not itself establish infringement. Estoppel.  

Geneoscopy could still defend the infringement lawsuit, but would generally be barred from repeating invalidity grounds it raised—or reasonably could have raised—in the IPR. That restriction is called estoppel. usc-cdn.house.gov

###

Sidebar 02:
Molecular Diagnostics Meets the Shipping Box

Behind these sophisticated molecular screening tests lies a decidedly practical challenge: preserving a usable specimen between the patient’s bathroom and the laboratory. Stool is a demanding biological environment, and home collection adds variation in handling, temperature, and shipping time. Identifying informative biomarkers accomplishes little if their signals deteriorate before testing. Preservation and transportation are integral parts of the diagnostic system.

Original Cologuard and Cologuard Plus analyze DNA, while Geneoscopy’s ColoSense analyzes RNA; all three also measure hemoglobin. 

DNA and RNA are substantially different analytical targets. Cologuard’s molecular components examine DNA methylation and, in the original test, mutations. ColoSense measures RNA expression. RNA is generally more vulnerable to degradation, making its reliable recovery a significant technical consideration. Nevertheless, both approaches face the shared requirement of delivering measurable human molecular material to the laboratory.

That creates an interesting patent question. Does Geneoscopy’s success in establishing that Exact’s claimed methods were obvious also narrow the protection available for ColoSense? 

Potentially, yes, for overlapping features. Earlier knowledge that defeats a broad claim covering sample collection and preservation is also relevant when assessing another company’s claims to those same methods. Changing the molecular target from DNA to RNA does not automatically make an otherwise obvious workflow inventive.

But the rulings do not establish that ColoSense as a whole is unpatentable—or invalidate Cologuard’s entire patent portfolio. The rulings addressed all 20 claims of Exact’s ’781 patent and the ten challenged claims of its ’746 patent. In the future, particular RNA extraction methods, preservation formulations, or biomarker combinations could present separate patentability questions. The revealing distinction is between a broadly applicable workflow assembled from known methods and a specific improvement that contributes something nonobvious. Substantial development and validation may be necessary in either case. 

Sidebar 3
An Obvious Combination—or Hindsight?

One exchange in the ’746 decision makes the competing arguments particularly tangible. The following paraphrases the parties’ positions and the Board’s reasoning.

The disputed method: Collect stool at home, divide it into two portions, preserve each portion appropriately, and send them to a laboratory for nucleic-acid and blood-protein testing without freezing.

Geneoscopy’s argument: The earlier literature already supplied the pieces—and reasons to combine them. Lenhard described combining stool DNA analysis with occult blood testing. Vilkin supplied an immunochemical blood-testing method with a collection tube and hemoglobin-preserving buffer. Itzkowitz supplied home collection and DNA stabilization for shipping without freezing. Geneoscopy argued that a skilled researcher would reasonably combine these methods to improve screening and make collection more convenient.

Exact’s rebuttal: That reconstruction assumes the route an inventor would take. Among its objections, Exact argued that a skilled researcher would have pursued a single preservative protecting both DNA and hemoglobin, avoiding the inconvenience of having patients divide their stool. Selecting separate portions and preservatives from different publications, Exact contended, reflected hindsight rather than an obvious development path.

The Board’s answer: A potentially better alternative does not make this combination nonobvious. The Board acknowledged that Exact’s single-preservative argument made sense in the abstract. It even discussed evidence suggesting such an approach might have been possible. But the existence of that alternative did not establish that the two-portion approach required invention.

The decisive factors were that the earlier techniques addressed the same screening problems, were available to a skilled researcher, and could be combined using their established functions. The combination needed to be a suitable option, rather than the best option. The Board therefore found a reason to combine the methods with a reasonable expectation of success.

This illustrates a subtle point: “A researcher might have preferred another design” does not necessarily establish that this design was nonobvious. The inquiry asks whether the claimed route was reasonably apparent from earlier knowledge, even if other routes were also available.

Source: ’746 Final Written Decision, February 5, 2026, printed pages 56–60.

Compare to PTO 21 page guide.   

The closest match is on PDF page 18: a preferable alternative does not necessarily make the claimed approach nonobvious. Four passages connect directly to the sidebar:

Guide passageConnection to the stool-testing argument
§2143.01(I), p. 18: “Desirable alternatives”The guide explains that a combination need not be the preferred or most desirable alternative to be obvious. This directly supports the Board’s response to Exact: a potentially better single-buffer approach does not establish that the two-portion approach was nonobvious.
§2143(I)(C), pp. 9–10: Applying a known improvement techniqueA known technique addressing a known problem can supply a reason to combine references, provided its application is within ordinary skill and the results are predictable. This matches Geneoscopy’s argument for bringing established blood-testing and DNA-preservation methods together.
§2143(I)(A), p. 2: Combining known elementsThe guide requires more than finding each component somewhere in the literature. It asks whether the elements could be combined through known methods, retain their functions, and yield predictable results. These are the factual connections Geneoscopy needed to establish.
§2143.02, pp. 19–20: Reasonable expectation of successA reason to try a combination is insufficient without a reasonable expectation that it would work. Absolute certainty is unnecessary, but evidence of technical unpredictability can support nonobviousness. This is where preservation difficulties could matter—if they undermined the proposed combination’s expected success.

The guide also supplies an important safeguard on page 1: invoking “common sense” or calling something “intuitive” does not substitute for an articulated explanation.

A compact addition to the sidebar:

The USPTO’s examination manual closely tracks this reasoning. It explains that an obvious combination need not be the preferred alternative, but requires more than assembling familiar ingredients on paper: there must be a reason to combine them and a reasonable expectation of success. The dispute therefore turned on whether the earlier methods supplied a workable, reasonably predictable route—not whether another preservation strategy might have been better.

Page numbers refer to the uploaded 21-page PDF.